ASH 2018: Emapalumab Safe and Effective in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis
Results suggest this monoclonal antibody should have a substantial impact on disease prognosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.